WallStreetZenWallStreetZen

NASDAQ: JAZZ
Jazz Pharmaceuticals PLC Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Jazz Pharmaceuticals earnings were $482.2M for the trailing 12 months ending Mar 31, 2025, with 48.9% growth year over year. The latest JAZZ earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$92.5M, down 148.4% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, JAZZ reported annual earnings of $560.1M, with 35% growth.

JAZZ past earnings growth

How has JAZZ's earnings growth performed historically?

Company
48.95%
Industry
11.53%
Market
34%
JAZZ's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
JAZZ's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
JAZZ's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

JAZZ earnings history

Current Revenue
$4.1B
Current Earnings
$482.2M
Current Profit Margin
11.9%
JAZZ's has demonstrated consistent long-term... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

JAZZ Return on Equity

Current Company
11.9%
Current Industry
-60.2%
Current Market
31.5%
JAZZ's Return on Equity (11.9%)... subscribe to Premium to read more.
High Return on Equity Performance

JAZZ undefined

Current Company
4.1%
Current Industry
-2.5%
JAZZ is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when JAZZ announces earnings.

JAZZ undefined

Current Company
5.69%
Current Industry
5.8%
JAZZ has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

JAZZ vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
JAZZ$1.25B$482.20M+9.63%$7.79
HALO$704.60M$485.36M+33.84%$3.85
LEGN-$153.44M-$218.15MN/A-$1.20
MDGL-$376.50M-$391.59MN/A-$17.93
CORT$110.98M$132.49M+6.66%$1.27
View Top Biotech Stocks

Jazz Pharmaceuticals Earnings Reports & History FAQ

What were Jazz Pharmaceuticals's earnings last quarter?

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q1 2025 earnings per share (EPS) of -$1.52, up 560.87% year over year. Total JAZZ earnings for the quarter were -$92.54 million. In the same quarter last year, Jazz Pharmaceuticals's earnings per share (EPS) was -$0.23.

If you're new to stock investing, here's how to buy Jazz Pharmaceuticals stock.

Is Jazz Pharmaceuticals profitable or losing money?

As of the last Jazz Pharmaceuticals earnings report, Jazz Pharmaceuticals is currently profitable. Jazz Pharmaceuticals's net profit (also called net income) for the twelve months ending Mar 31, 2025 was $482.20 million, a 45.77% increase year over year.

What was JAZZ's earnings growth in the past year?

As of Jazz Pharmaceuticals's earnings date in Q2 2025, Jazz Pharmaceuticals's earnings has grown 48.95% year over year. This is 37.42 percentage points higher than the US Biotechnology industry earnings growth rate of 11.53%. JAZZ earnings in the past year totalled $482.20 million.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.